Redeye provides an update on IRLAB after the company's Q3 report, which showed costs below our expectations but followed last week's announcement that a partnering deal in 2026 is now less likely. We lower our valuation to reflect a later deal and higher dilution, and see the coming year as one where partnering progress and the LIFT-PD readout in mid-2027 will be key.
LÄS MER